Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP2004/051104

International filing date: 14 June 2004 (14.06.2004)

Document type: Certified copy of priority document

Document details: Country/Office: EP
Number: 03101801.3
Filing date: 19 June 2003 (19.06.2003)

Date of receipt at the International Bureau: 02 February 2007 (02.02.2007)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung   Certificate   Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr.   Patent application No.   Demande de brevet n°

03101801.3

REC'D 0 7 FEB 2007
WIPO   PCT

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

Anmeldung Nr:
Application no.:   03101801.3
Demande no:

Anmeldetag:
Date of filing: 19.06.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Poalis A/S
Thorvaldsensvej 40
1871 Frederiksberg C
DANEMARK

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

A method of producing a low molecular weight organic compound in a cell.

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s) revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C12P/

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

TITLE: A method of producing a low molecular weight organic compound in a cell.

FIELD OF THE INVENTION:

5   The present invention relates to a method of producing a low molecular weight organic compound (e.g. a plant or bacteria secondary metabolite) in increased yields involving use of a cell (e.g. a plant or microorganism cell), which comprises a gene involved in the biosynthesis pathway leading to a low molecular weight organic aglycon compound and a glycosyltransferase gene capable of glycosylating the produced aglycon.

10

BACKGROUND OF THE INVENTION:

Plants and microbes synthesize a large number of natural substances, in particular secondary metabolites, with diverse and generally unclear function. In contrast to the primary metabolites
15 (e.g. amino acids, sugars, fatty acids), which are involved in fundamental functions like metabolism, growth, maintenance and survival, secondary metabolites are not required for fundamental functions. Many secondary metabolites from plants are known to act as repellants or natural pesticides in defense against herbivore animals or as sexual attractants to pollinating insects (Grisebach, 1988, In: European Conference on Biotechnology, Scientific, technical and
20 industrial challenges, Verona, Italy, 7-8 November 1988, pages 23-27), whereas fungal secondary metabolites often act as phytotoxins (Osbourn, 2001, Proceedings of the National Academy of the USA 98: 14187-14188).

Various secondary metabolites from more than 100 different plant species have been shown to
25 exert antimicrobial activity (Cowan, 1999, Clinical Microbiology Reviews 12: 564-582) and a large number of secondary metabolites from common food plants are not only responsible for the taste and color but are also believed to have health promoting activities (Eastwood, 2001, Quarterly Journal of Medicine 94: 45-48; Drewnowski & Gomez-Cameros, 2000, American Journal of Clinical Nutrition 72: 1424-1435). Accordingly, these natural substances are
30 economically important in such different fields as drugs, food additives, fragrances, pigments, and pesticides.

Secondary metabolites often accumulate in small quantities and sometimes only in specialized cells. Hence their extraction can be difficult and inefficient. In spite of the progress in organic chemical synthesis, a large number of these metabolites have such complex structures that they are virtually impossible to synthesize at economic levels. Moreover, the natural product is

5   generally more acceptable to consumers than an artificially produced one. Consequently, industrial application of these substances and their functional analogues often relies on natural extraction from plants.

Secondary metabolites may generally be structurally qualified as low molecular weight organic

10   compounds.

Industrial production of secondary metabolites or other natural and non natural low molecular weight organic compounds can be facilitated by a biotechnological approach. By transformation of genes involved in the biosynthesis of a desired natural product, plants or microbes can e.g. be

15   manipulated to produce a compound not previously present in the plant or organism.

Glycosyltransferase may be defined as an enzyme which transfers residues of sugars (galactose, xylose, rhamnose, glucose, etc) to acceptor molecules. Acceptor molecules may be other sugars, proteins, lipids and other organic substrates. The acceptor molecule may be termed an aglycon

20   (aglucone if sugar is glucose). An aglycon may be defined as the non-carbohydrate part of a glycoside. A glycoside may be defined as an organic molecule with a glycosyl group (organic chemical group derived from a sugar or starch molecule) connected to it by way of e.g. an intervening oxygen atom.

25   These glycosylated molecules take part in diverse metabolic pathways and processes. The transfer of a glycosyl moiety can alter the acceptor's bioactivity, solubility and transport properties e.g. within a plant or microbial cell and throughout the plant.

The art describes a number of glycosyltransferases that can glycosylate compounds such as

30   secondary metabolites from e.g. plants and fungi (Paquette, S. et al, Phytochemistry 62 (2003) 399-413).

3

WO01/07631, WO01/40491 and (Arend, J et al., Biotech. & Bioeng (2001) 78:126-131)
describe that at least some of these glycosyltransferases are capable of glycosylating a number of
different structurally related secondary metabolites and other structurally related low molecular
weight organic compounds.

5

Accordingly, the skilled person has at his disposal a number of different glycosyltransferases
capable of glycosylating numerous different secondary metabolites and other structurally related
low molecular weight organic compounds. .

10   Tattersall, DB et al, Science (2001) 293:1826-8 describes that the entire pathway for synthesis
of the tyrosine-derived cyanogenic glucoside dhurrin [a seconday metabolite] has been
transferred from the plant *Sorghum bicolor* to the plant *Arabidopsis thaliana*. The entire
pathway for synthesis included two genes involved in the biosynthesis pathway (CYP79A1 and
CYP71E1) and a glucosyltransferase (sbHMNGT) capable of glucosylating the last intermediate
15   (p-hydroxymandelonitrile) to get the glucoside dhurrin (see Figure 1 herein). It was
demonstrated that the transgenic *Arabidopsis thaliana* plant was capable of producing 4 mg of
dhurrin per gram of fresh weight.

Arend, J et al., Biotech. & Bioeng (2001) 78:126-131 and WO01/07631 describes cloning of a
20   glucosyltransferase from the plant *Rauvolfia serpentina*. The cloned glucosyltransferase was
inserted into E. coli bacteria. When the aglucones hydroquinone, vanillin and p-
hydroxyacetophenone were added to the medium of cultivated cells of the engineered E. coli, the
corresponding glucosides, arbutin, vanillin-D-glucoside and picein were synthesized. They also
were released from the cells into the surrounding medium.

25

Moehs, CP et al, Plant Journal (1997) 11:227-236 describes that a cDNA encoding a solanidine
glucosyltransferase (SGT) was isolated from potato. The cDNA was selected from a yeast
expression library using a positive selection based on the higher toxicity of steroidal alkaloid
aglycons relatively to their corresponding glycosylated forms. The activity of the cloned SGT
30   was tested in an *in vitro* assay based on isolated recombinant produced SGT.

US6372461 describes a method for making the secondary metabolite vanillin by use of an E. coli cell where there has been introduced genes involving in the biosynthesis pathway starting from glucose and leading to vanillic acid. The recombinant E. coli can produce vanillic acid when cultured in a medium comprising glucose. The produced vanillic acid is recovered from the 5 fermentation broth and reduced to vanillin with aryl-aldehyde dehydrogenase.

SUMMARY OF THE INVENTION:

The problem to be solved by the present invention is to provide a new method of producing in 10 particular low molecular weight organic compounds of interest, wherein the method provides the possibility of obtaining the compound in higher yields.

Among other things, the solution is based on that the present inventors have investigated and compared the following two cultivated microorganisms:

15   (i)   a microorganism comprising a gene involved in the biosynthesis pathway leading to a low molecular weight aglycon compound; and

     (ii)   the same microorganism but where there is also introduced a glycosyltransferase gene capable of glycosylating the produced aglycon to get the associated glycosylated form of the aglycon.

20

The inventors found that the microorganism with the glycosyltransferase during culture fermentation is capable of producing higher amounts of the glycosylated form of the aglycon as compared to the amounts of the corresponding aglycon produced by the microorganism without the glycosyltransferase. See working examples herein for an illustrative example where an E. coli 25 cell of type (ii) above produces higher amounts of vanillin glucoside as compared to the amounts of the corresponding vanillin aglucone produced in a corresponding E. coli without the glycosyltransferase (E. coli cell of type (i) above).

Accordingly, a microorganism cell of the type (ii) above may then be used to obtain the 30 glycosylated form of the corresponding aglycon in high amounts. However, it may also be used in a process to make the aglycon in higher amounts simply by e.g. first making the glycosylated

5

form of the aglycon, recovering it and deglycosylate it according to standard protocols (e.g. enzymatically by use of a β-glucosidase or by adequate chemical hydrolysis.)

Accordingly, a first aspect of the invention relates to a method of producing a low molecular

5   weight organic compound comprising following steps:

a) fermenting a microorganism cell or a filamentous fungi cell, which comprises a gene encoding a product involved in the biosynthetic pathway leading to a low molecular weight organic aglycon compound and a heterologous glycosyltransferase gene encoding a glycosyltransferase capable of glycosylating the produced aglycon, in a suitable

10   medium, wherein the cell produces the aglycon and the corresponding glycosylated form of the aglycon; and

b) recovering the glycosylated form of the aglycon compound;

(i) wherein the low molecular weight organic aglycon compound has a molecular weight from 50 to 3000 g/mol, and

15   (ii) wherein the glycosyltransferase is a glycosyltransferase capable of conjugating a sugar to the aglycon compound, wherein the sugar is a sugar selected from the group consisting of galactose, glucosamine, N-acetylglucosamine, xylose, glucuronic acid, rhamnose and glucose.

20   A second aspect of the invention relates to a microorganism cell or a filamentous fungi cell that comprises a gene encoding a product involved in the biosynthetic pathway leading to a low molecular weight organic aglycon compound and a heterologous glycosyltransferase gene encoding a glycosyltransferase capable of glycosylating the produced aglycon, wherein the cell, when fermented in a suitable medium, produces the aglycon and the corresponding glycosylated

25   form of the aglycon, and wherein the glycosyltransferase is a glycosyltransferase capable of conjugating a sugar to the aglycon compound, wherein the sugar is a sugar selected from the group consisting of galactose, glucosamine, N-acetylglucosamine, xylose, glucuronic acid, rhamnose and glucose.

30   As said above, the basic principle behind the method described above may be used to produce an aglycon of interest.

6

Accordingly, a third aspect of the invention relates to a method of producing a low molecular weight organic aglycon compound comprising following steps:

a) growing a cell, which comprises a gene encoding a product involved in the biosynthesis pathway leading to a low molecular weight organic aglycon compound and a

5   glycosyltransferase gene encoding a glycosyltransferase capable of glycosylating the produced aglycon, under suitable conditions wherein the cell produces the aglycon and the associated glycosylated form of the aglycon;

b) deglycosylating the glycosylated form of the aglycon; and

c) recovering the aglycon compound;

10   (i) wherein the low molecular weight organic aglycon compound has a molecular weight from 50 to 3000, and

(ii) wherein the glycosyltransferase is a glycosyltransferase capable of conjugating a sugar to the aglycon compound.

15   An advantage of using a glycosyltransferase in a method as described herein may further be to use the different specificities of known glycosyltransferases. For instance, it is known that some glycosyltransferases are enantiomer specific (see e.g. Jones, P et al, J. of Biological Chemistry (1999), 274:35483-35491 and WO03/023035). Consequently, if one for instance wants to make a specific enantiomer for e.g. an aglycon then one could choose to use such an enantiomer

20   specific glycosyltransferase.

A fourth aspect of the invention relates to a method for selecting a cell with increased production of a glycosylated form of a low molecular weight organic aglycon compound comprising following steps:

25   a) growing a cell, which comprises a gene encoding a product involved in the biosynthesis pathway leading to a low molecular weight organic aglycon compound and a glycosyltransferase gene encoding a glycosyltransferase capable of glycosylating the produced aglycon, under suitable conditions wherein the cell produces the aglycon and the corresponding glycosylated form of the aglycon;

30   b) treating the cell in a way that changes the expression level of at least one gene involved in the biosynthesis pathway leading to a low molecular weight organic aglycon

and/or the glycosyltransferase gene capable of glycosylating the produced aglycon in order to make a library of cells with different expression levels of the genes; and

c) selecting a cell that produces a higher amount of the glycosylated form of the aglycon as compared to the cell of step a);

5   (i) wherein the low molecular weight organic aglycon compound has a molecular weight from 50 to 3000, and

(ii) wherein the glycosyltransferase is a glycosyltransferase capable of conjugating a sugar to the aglycon compound.

10 Example 8 herein describes how this method is used to make an *Arabidopsis thaliana* plant capable of producing increased mg of the glucoside dhurrin per gram of fresh weight. The starting cell of step a) is the *Arabidopsis thaliana* transgenic cell described in Tattersall, DB et al, Science (2001) 293:1826-8. As explained above the *Arabidopsis thaliana* transgenic cell comprises the entire pathway for synthesis of the cyanogenic glucoside dhurrin. It was

15 demonstrated that the transgenic *Arabidopsis thaliana* plant was capable of producing 4 mg of dhurrin per gram of fresh weight. After performing the selecting method as described in example 8 an *Arabidopsis thaliana* transgenic cell is selected in step c) that produces more than 6 mg of dhurrin per gram of fresh weight.

20 Without being limited to theory, it is believed to be the first time that a transgenic plant has been provided that is capable of producing more than 4 mg per gram of fresh weight of a glycosylated form of a low molecular weight organic aglycon compound.

Accordingly, a fifth aspect of the invention relates to a transgenic plant capable of producing

25 more than 5 mg per gram of fresh weight of a glycosylated form of a low molecular weight organic aglycon compound,

(i) wherein the low molecular weight organic aglycon compound has a molecular weight from 50 to 3000.

30 **DEFINITIONS:**

8

Prior to a discussion of the detailed embodiments of the invention is provided a definition of specific terms related to the main aspects of the invention.

The term "aglycon" denotes non-carbohydrate part of the corresponding glycosylated form of
5   the aglycon. It may also be defined as an acceptor compound capable of being conjugated to a sugar. In a number of relevant examples, the aglycon is an alcohol with a hydroxy group suitable for being glycosylated. An example of this is p-hydroxymandelonitrile (see figure 1) which has a hydroxy group that can be conjugated (glycosylated) with glucose to get dhurrin. (dhurrin is here the corresponding glycosylated form of the aglycon p-hydroxymandelonitrile). In this example,
10   wherein the sugar is glucose the aglycon may be termed aglucone. Further, when the sugar is glucose the term glucosylated may be used instead of glycosylated.
An aglycon may also be glycosylated at different group than a hydroxy group, in particular at other nucleophilic groups such as a carboxylic acid, SH-, nitrogen, amine or C-C group.

15   The term "gene encoding a product involved in the biosynthesis pathway leading to a low molecular weight aglycon compound" should be understood according to the art as a gene encoding a product involved in the biosynthesis pathway leading to a low molecular weight aglycon compound. The gene encoded product is normally a polypeptide. However the product may also for instance be a RNA molecule affecting the expression of a gene. The encoded
20   product of the gene may be directly involved in the biosynthesis pathway or indirectly via e.g. other precursors or intermediated. The important issue, independently of the precise mechanism behind it, is that the gene makes it possible for the cell to synthesize the aglycon compound of interest as described herein. The art describes numerous suitable examples of such genes. Just for illustration one example could be CYP71E1 from *Sorghum bicolor* that starting from p-
25   hydroxyphenylacetonitrile is involved the biosynthesis pathway leading to a low molecular weight aglycon compound p-hydroxymandelonitrile (see Figure 1 herein and Tattersall, DB et al, Science (2001) 293:1826-8). Further examples are the genes involved in the biosynthesis pathway leading to a low molecular weight aglycon compound vanillin as described in working examples herein.

30

The term "glycoside" denotes a compound which on hydrolysis gives a sugar and a non-sugar (aglycon) residue, e.g. glucosides give glucose, galactosides give galactose.

The term "glycosyltransferase" denotes a glycosyltransferase capable of conjugating a sugar to an aglycon as described herein. The sugar may e.g. be D and L isomers of galactose, glucosamine, xylose, glucuronic acid, rhamnose or glucose. Alternatively the sugar may be a

5   carbohydrate derivative such as e.g. inositol, D-olivose, rhodinose and etc available as nucleotide dephosphates. Further the sugar may for instance be e.g. a monosaccharide, a disaccharide or a trisaccharide. If the sugar is glucose the glycosyltransferase may be termed a glucosyltransferase.

10   The term "growing a cell" in relation to step a) of the third aspect should be understood broadly in the sense of growing a cell under suitable conditions (temperature, nutrients etc.) that allows growth of the cell. If the cell is e.g. a plant cell this means e.g. growth of the plant cell under conditions where e.g. a mature plant is obtained. If the cell is a microorganism this could e.g. be fermenting of the microorganism cell in a suitable medium where the microorganism is capable

15   of growing.

The term "recovering" in relation to "recovering the glycosylated form of the aglycon compound" of step b) of the first aspect of the invention and "recovering the aglycon compound" of step c) of third aspect of the invention should be understood broadly in the sense

20   that the compound is recovered from the cell or from e.g. the supernatant of the medium where the cell for instance is fermented in order to get the compound in a higher purity than before the recovery step. The recovery step may include more or less detailed purification steps. Preferably the compound is at some point after the recovery step present in a composition where the composition comprises at least 4% (w/w) of the compound, more preferably at least 10% (w/w)

25   of the compound, even more preferably at least 20% (w/w) of the compound and most preferably at least 50% (w/w) of the compound. The skilled person is aware of suitable purification protocols (e.g. by using adequate purification columns) to obtain the desired purity. Preferably after recovering there is recovered at least 10 mg compound, more preferably there is recovered at least 1 g compound, even more preferably there is recovered at least 10 g

30   compound, and most preferably there is recovered at least 500 g compound. Preferably there is recovered from 10 mg to 100 kg compound.

10

Embodiment(s) of the present invention is described below, by way of example(s) only

DRAWINGS:

5   Figure 1: Shows the pathway for synthesis of the tyrosine-derived cyanogenic glucoside dhurrin (a seconday metabolite). The pathway for synthesis included two genes involved in the biosynthesis pathway (CYP79A1 and CYP71E1) and a glucosyltransferase (sbHMNGT) capable of glucosylating the last intermediate (p-hydroxymandelonitrile) to get the glucoside dhurrin.

10   **DETAILED DESCRIPTION OF THE INVENTION:**

Cell

The cell suitable to growth as specified under step a) of the method of the third aspect of the
15   invention may be any suitable cell such as any eukaryotic or prokaryotic cell. Preferably the cell is a cell selected from the group consisting of a plant cell, a filamentous fungal cell and a microorganism cell.

Plants which include a plant cell according to the invention are also provided as are seeds
20   produced by said plants.

In a preferred embodiment of the invention said plant is selected from: corn (Zea. mays), canola (Brassica napus, Brassica rapa ssp.), alfalfa (Medicago sativa), rice (Oryza sativa), rye (Secale cerale), sorghum (Sorghum bicolor, Sorghum vulgare), sunflower (helianthus annuas), wheat
25   (Tritium aestivum and other species), Triticale, Rye (Secale) soybean (Glycine max), tobacco (Nicotiana tabacum), potato (Solanum tuberosum), peanuts (Arachis hypogaea), cotton (Gossypium hirsutum), sweet potato (Impomoea batatus), cassava (Manihot esculenta), coffee (Cofea spp.), coconut (Cocos nucifera), pineapple (Anana comosus), citrus (Citrus spp.) cocoa (Theobroma cacao), tea (Camellia senensis), banana (Musa spp.), avacado (Persea americana),
30   fig (Ficus casica), guava (Psidium guajava), mango (Mangifer indica), olive (Olea europaea), papaya (Carica papaya), cashew (Anacardium occidentale), macadamia (Macadamia intergrifolia), almond (Primus amygdalus), apple (Malus spp), Pear (Pyrus spp), plum and

cherry tree (Prunus spp), Ribes (currant etc.), Vitis, Jerusalem artichoke (Helianthemum spp), non-cereal grasses (Grass family), sugar and fodder beets (Beta vulgaris), chicory, oats, barley, vegetables, and ornamentals.

5   Preferably, plants of the present invention are crop plants (for example, cereals and pulses, maize, wheat, potatoes, tapioca, rice, sorghum, millet, cassava, barley, pea, and other root, tuber or seed crops. Important seed crops are oil-seed rape, sugar beet, maize, sunflower, soybean, and sorghum or plants grown for their use as spices or pharmaceutical products (Mentha spp, clove, Artemesia spp, Thymus spp, Lavendula spp, Allium spp., Hypericum, Catharanthus spp,

10   Vinca spp, Papaver spp., Digitalis spp, Rawolfia spp., Vanilla spp., Petrusilium spp., Eucalyptus, tea tree, Picea spp, Pinus spp, Abies spp, Juniperus spp,. Horticultural plants to which the present invention may be applied may include lettuce, endive, and vegetable brassicas including cabbage, broccoli, and cauliflower, and carnations and geraniums.

15   The present invention may be applied in tobacco, cucurbits, carrot, strawberry, sunflower, tomato, pepper, Chrysanthemum.

Grain plants that provide seeds of interest include oil-seed plants and leguminous plants. Seeds of interest include grain seeds, such as corn, wheat, barley, nee, sorghum, rye, etc. Oil-seed

20   plants include cotton soybean, safflower, sunflower, Brassica, maize, alfalfa, palm, coconut, etc. Leguminous plants include beans and peas. Beans include guar, locust bean, fenugreek, soybean, garden beans, cowpea, mungbean, lima bean, fava been, lentils, chickpea.

In a further preferred embodiment of the invention said plant is selected from the following

25   group: maize; tobacco; oil seed rape; potato; soybean.

The whole genome of *Arabidopsis thaliana* plant has been sequenced (Paquette, S. et al, Phytochemistry 62 (2003) 399-413). Consequently, very detailed knowledge is available for this plant and it may therefore be a preferred plant cell to work with.

30

Accordingly, a very preferred plant cell is an *Arabidopsis* cell and in particular an *Arabidopsis thaliana* cell.

Filamentous fungi includes all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are characterized by a vegetative mycelium composed of chitin, cellulose, glucan, chitosan, mannan, and other complex

5 polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as Saccharomyces cerevisiae is by budding of a unicellular thallus and carbon catabolism may be fermentative.

In a more preferred embodiment, the filamentous fungal cell is a cell of a species of, but not

10 limited to, Acremonium, Aspergillus, Fusarium, Humicola, Mucor, Myceliophthora, Neurospora, Penicillium, Thielavia, Tolypocladium, and Trichoderma or a teleomorph or synonym thereof.

A preferred microorganism cell suitable to be used in a method as described herein is a microorganism cell selected from the group consisting of a yeast cell and prokaryotic cell.

15

A preferred yeast cell is selected from the group consisting of *Saccharomyces spp* e.g. *Saccharomyces cerevisiae*; and *Pichia spp*.

In a method as described herein a very preferred cell is a prokaryotic cell. A preferred

20 prokaryotic cell is selected from the group consisting of Bacillus, Streptomyces, Corynebacterium, Pseudomonas and in particular an E. coli cell.

A preferred Bacillus cell is B. subtilis, B. amyloliquefaciens or B. licheniformis.

25 A preferred cell is a cell without active genes encoding a beta-glycosidase. Further, it is preferred that the cell comprises a permease or other transport protein enabling the cell to release or secrete the glycoside to the medium or to another internal compartment than the one where it is glycosylated.

30 Transformation of suitable DNA containing vectors into the cells described above is routine work for the skilled person. Suitable vectors can be constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation

sequences, enhancer sequences, marker genes and other sequences as appropriate. For further details see, for example Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995; Harwood, C. R., and Cutting, S. M. (eds.)

5   "Molecular Biological Methods for Bacillus". John Wiley and Sons, 1990).
In relation to examples of suitable plant cell vectors and suitable plant transformation techniques reference is made to WO02/103022. In relation to filamentous fungi cells reference is made to EP869167.

10   Preferably, the cell is a cell wherein the cell expresses a heterologous glycosyltransferase gene as described herein, in particular a microorganism cell or a filamentous fungi cell that expresses a heterologous glycosyltransferase gene as described herein.

In this connection, the term "heterologous glycosyltransferase gene" should be understood
15   according to the art as a glycosyltransferase gene that have been introduced into a cell that, before the introduction, did not express the glycosyltransferase gene.

Glycosyltransferase:

20   As described above, the art describes a number of glycosyltransferases that can glycosylate a low molecular weight organic compound of interest such as secondary metabolites from e.g. plants and fungi. Based on DNA sequence homology of the sequenced genome of the plant *Arabidopsis thaliana* it is believed to contain around 100 different glycosyltransferases. These and numerous others have been analyzed in Paquette, S. et al, Phytochemistry 62 (2003) 399-
25   413. Figure 1 of this article is a so-called multiorganism tree providing names of numerous suitable glycosyltransferases.

WO01/07631, WO01/40491 and (Arend, J et al., Biotech. & Bioeng (2001) 78:126-131) describe that at least some of these glycosyltransferases are capable of glycosylating a number of
30   different structurally related secondary metabolites and other structurally related low molecular weight organic compounds.

14

Accordingly, the skilled person has at his disposal a number of different glycosyltransferases capable of glycosylating numerous different secondary metabolites and other low molecular weight organic compounds. This fact is described in further details below by way of some illustrative specific examples.

5

Although glucosyltransferases are generally thought to be relatively substrate specific it has been shown that other substrates can be processed at significant levels if they are presented to the enzyme. It has been shown that expression of the sorghum CYP79A1 in Arabidopsis resulted in the production of large amounts p-hydroxybenzylglucosinolate, which is not a naturally occuring

10 glucosinolate (S-glucoside) of Arabidopsis (Bak et al, 2000, Plant Physiology 123: 1437-1448). The new glucosinolate is produced from p-hydroxyphenylacetaldoxime, which is formed from tyrosine by CYP79A1 and subsequently channeled into the pre-existing glucosinolate biosynthetic pathway and to the associated glucosyltransferases.

15 Moreover, a glucosyl transferase, arbutin synthase, isolated from the medicinal plant Rauvolfia serpentina was shown to have considerable activity to other substrates than the native hydroquinone (Arend et al, 2001, Biotechnology and Bioengineering 76: 126-131). When some of these substrates, like vanillin or p-hydroxyacetophenone, were fed to cultures of E. coli that had been engineered to express the plant glucosyl transferase the substances were taken up and

20 converted to their corresponding glucosides, vanillin-ß-D-glucoside and picein. These two products, both of which are of commercial interest, were subsequently released from the bacteria.

These examples show that glucosyl transferases can act on substrates that are normally not

25 present in the metabolic pathway and that this can lead to the formation of novel glucosides of natural products.

As said above the skilled person has at his disposal a number of different glycosyltransferases capable of glycosylating numerous different secondary metabolites and other low molecular

30 weight organic compounds. Further, he may by use of known routine methods easily identify further suitable glycosyltransferases capable of glycosylating specific low molecular weight organic compounds of interest. Below are given some examples of such suitable methods.

The numerous known DNA glycosyltransferase sequences may be used to make appropriate PCR primers to clone new glycosyltransferases. This could e.g. be done by a method comprising following steps:

5   (a) preparing a cDNA library from a cell (e.g. plant tissue cell) expressing glucosyltransferases,

(b) using relevant known DNA glycosyltransferase sequences to make appropriate PCR primers to amplify part of the glucosyltransferase cDNA from the cDNA library,

(c) using the DNA obtained in steps (b) as a probe to screen the DNA library prepared from cell expressing glucosyltransferases, and

10   (e) identifying and purifying vector DNA comprising an open reading frame encoding a glucosyltransferase of interest.

Alternatively, a suitable glucosyltransferase may be identified by use of a so-called expression cloning strategy. A suitable expression cloning strategy could be a method comprising following

15   steps:

(a) preparing a cDNA library from a cell (e.g. plant tissue cell) expressing glucosyltransferases;

(b) introducing the cDNA library into expression cells by use of an expressing vector that gives expression (transcription and translation) of the cDNA in a growing expression cell of interest;

(c) growing the cell in a medium comprising a toxic amount of a low molecular weight organic

20   aglycon compounds of interest (i.e. only specific individual cells comprising an expressed glucosyltransferase capable of glycosylating the aglycon of interest will be able to grow);

(d) isolating one or more of the growing cells and identify one that expresses the glucosyltransferase of interest.

25   As described in Moehs, CP et al, Plant Journal (1997) 11:227-236 this expression cloning strategy may be done by use of a yeast cell. The teaching of the present invention demonstrates that the glycosylated form of the aglycon is less toxic to bacteria as compared to the corresponding aglycon as such. Consequently, this expression cloning strategy may be done by use of bacterial cells such as E. coli.

30

Accordingly, a separate aspect of the invention relates to expression cloning method for obtaining a glucosyltransferase of interest comprising following steps:

16

(a) preparing a cDNA library from a cell (e.g. plant tissue cell) expressing glucosyltransferases;

(b) introducing the cDNA library into bacterial expression cells by use of an expression vector that gives expression (transcription and translation) of the cDNA in a growing expression cell of interest;

5   (c) growing the cell in a medium comprising a toxic amount of a low molecular weight organic aglycon compounds of interest (i.e. only specific individual cells comprising an expressed glucosyltransferase capable of glycosylating the aglycon of interest will be able to grow);

(d) isolating one or more of the growing cells and identify one that expresses the glucosyltransferase of interest.

10

Preferably, the bacterial expression cells of step (b) are E. coli cells.

An advantage of an expression cloning strategy as described above it that one directly gets a glucosyltransferase capable of glycosylating the aglycon of interest.

15

Preferably, the glycosyltransferase is a capable of conjugating a sugar to the aglycon compound, wherein the sugar is a sugar selected from the group consisting of galactose, glucosamine, N-acetylglucosamine, xylose, glucuronic acid, rhamnose and glucose.

20   In a further preferred embodiment, the glycosyltransferase is a UDPG-glycosyltransferase (UGT). UGTs have been identified in plants, animals, fungi, bacteria and viruses. These glycosyltransferases are characterized by utilization of UDP-activated sugar moeties as the donor molecule and contain a conserved UGT-defining sequence motif near the C-terminus. See (Paquette, S. et al, Phytochemistry 62 (2003) 399-413) for further details in relation to the

25   definition of this UDPG-glycosyltransferase family.

Preferably, the glycosyltransferase is a glycosyltransferase that conjugates a monosaccharide or a disaccharide sugar to an aglycon as described herein. Most preferably glycosyltransferase is a glycosyltransferase that conjugates a monosaccharide sugar to an aglycon as described herein.

30

In a preferred embodiment, the glycosyltransferase is a glucosyltransferase.

Below are described examples of some suitable glycosyltransferases.

WO01/40491 describes cloning of a glycosyltransferase from the plant *Sorghum bicolor* named sbHMNGT. This and the related homologous glycosyltransferases as described in WO01/40491

5   are capable of glycosylating at least following low molecular weight organic aglycon compounds (see Table 3 of WO01/40491):

Cyanohydrins

1) mandelonitrile

p-hydroxymandelonitrile

10 3) acetone cyanohydrin

benzyl derivatives

4) hydroquinone

5) benzyl alcohol

6) p-hydroxybenzyl alcohol

15 7) benzoic acid

8) p-hydroxybenzoic acid

9) p-hydroxybenzaldehyde

10) gentisic acid

11) caffeic acid

20 12) 2-hydroxy cinnamic acid

13) resveratrol (stilbene)

14) salicylic acid

15) p-hydroxymandelic acid

16) vanillic acid

25 17) vanillin

18) 2-hydroxy methoxybenzylalcohol

flavonoids

19) quercetin (flavonol)

20) cyanidin (anthocyanidin)

30 21) biochanin A (isoflavone)

22) naringenin (flavanone)

23) apigenin (flavone)

hexanol derivatives

24) 1-hexanol

25) trans hexen-1-ol

26) cis hexen-l-ol

5 27) 3-methyl hexen-1-ol

28) 3-methyl hexen-1-ol

29) indole acetic acid (plant hormone)

30) geraniol (monoterpenoid)

31) tomatidine (alkaloid)

10 32) nerol

33) p-citronellol

Arend, J et al., Biotech. & Bioeng (2001) 78:126-131 describes cloning of a glycosyltransferase

from the plant *Rauvolfia serpentina*. It is capable of glycosylating at least following low

15 molecular weight organic phenolic aglycon compounds (see table 1):

Hydroquinone, Vanillin, Saligerin, Resorcinol, Thymol, Phenol, Methylvanillin, p-

Hydroxyacetophenone, Vanillic acid, p-Methoxyphenol, 3,4-Dimethoxyphenol, Coniferyl

alcohol, o-Coumaric Acid, p-Coumaric Adic.

20 WO01/59140 describes a glycosyltransferase from the plant *Arabidopsis thaliana*. It is capable

of glycosylating at least following low molecular weight organic aglycon compounds: caffeic

acid, luteolin, quercitin-, catechinl-, syadinin.

WO02/103022 describes a glycosyltransferase from the plant *Arabidopsis thaliana*. It is capable

25 of glycosylating at least following low molecular weight organic aglycon compounds:

Benzoate substrates, in particular p-hydroxybenzoic acid.

WO03/02035: describes a glycosyltransferase from the plant *Arabidopsis thaliana*. It is capable

of glycosylating at least following low molecular weight organic aglycon phytohormone

30 compound: Abscisic acid.

19

Below are described suitable assays to measure the activity of a glycosyltransferase of interest. The assays are described for a glucosyltransferase. However when sugar is not glucose, one just has to use the adequate sugar (e.g. galactose) in stead of the glucose.

5 The ability of a glucosyltransferase to conjugate an aglycon of interest to glucose can for example be determined in an assay comprising the following steps.
   a) Incubation of a reaction mixture comprising ^{14}C_UDP-glucose, aglycon and UDPglucose:aglycon-glucosyltransferase at 30°C between 2 minutes and 2 hours
   b) terminating the reaction, and
10 c) chemical identification and quantification of the glucoside produced.

Typically the reaction mixture has a volume of 5 to 2000 µl, but preferably 20 µl and includes 10-200 mM TrisHCI (pH 7.9); 1-5 µM ^{14}4C-UDP-glucose (about 11.0 GBq mmol-1); 0-300 µM UDP-glucose; 0-20 mM aglycone; 25 mM γ-gluconolactone; 0-2 µg/µl BSA and 0-10 ng/µl
15 UDP-glucose:aglycon-glucosyltransferase. β-glucosidase inhibitors other than γ-gluconolactone and protein stabilizers other than BSA may be included as appropriate. One possibility to terminate the reaction is to acidify the reaction mixture for example by adding 1/10 volume of 10% acetic acid.

20 Chemical identification and quantification of the glucoside formed in the reaction mixture may be achieved using a variety of methodologies including NMR spectroscopy, TLC analysis, HPLC analyses or GLC analysis in proper combinations with mass spectrometric analysis of the glucoside.
   Reaction mixtures for analysis by NIVIR spectroscopy usually have a total volume of 0.5-1 ml,
25 are incubated for 2 hours and include 0-10mM aglycon, e.g.2 mM p-hydroxy-mandelonitrile or 6.5 mM geraniol, 3 mM UDP-glucose, 2.5 µg gluceryltransferease, and 0.5 mg BSA. Glucosides are extracted for example with ethyl acetate and lyophillized prior to NMR analysis.

For TLC analysis the reaction mixtures are applied to Silica Gel 60 F254 plates (Merck), dried
30 and eluted in a solvent such as ethyl acetate : acetone : dichloromethane : methanol H_2O (40:30:12:10:8, v/v). Plates are dried for one hour at room temperature and exposed to storage phosphor imaging plates prior to scanning on a PhosphorImager. Based on the specific

radioactivity of the radiolabelled UIDP-glucose, the amount of glucoside formed is quantified. The radioactivity may also be determined by liquid scintillation counting (LSC analysis). In some.cases, where the glucoside formed is derived from a very hydrophobic aglycon, e.g. mandelonitrile, the glucoside can be extracted into an ethyl acetate phase and thereby be

5 separated from unincorporated ^{14}C-UDP-glucose. 2 ml of scintillation cocktail are added to 250 μl of each ethyl acetate extract and analyzed using a liquid scintillation counter. During column fractionation, those fractions containing gluceryltransferase activity can be identified using the aglycon substrate of interest and ethyl acetate extraction of the glucoside formed.

10 A glycosyltransferase gene as described herein may be introduced into a cell in order to make a cell wherein the cell expresses a heterologous glycosyltransferase gene as described herein, in particular a microorganism cell or a filamentous fungi cell that expresses a heterologous glycosyltransferase gene as described herein.

15 <u>A gene involved in the biosynthesis pathway</u>

As said above, the term a "gene encoding a product involved in the biosynthesis pathway leading to a low molecular weight aglycon compound" should be understood according to the art as a gene encoding a product involved in the biosynthesis pathway leading to a low molecular weight

20 aglycon compound.

The art describes numerous suitable examples of such genes and the numbers are exponentially increasing since a number of whole genomes of different plant and microorganisms are continuously published.

25

Reference may for example be made to the textbook "Biochemistry & Molecular Biology of Plants", edited by Bob B. Buchanan et al, ISBN 0-943088-37-2. Chapter 24: "Natural Product (Secondary Metabolites)" describes examples of a number of different suitable genes involved in the biosynthesis pathway leading to a low molecular weight aglycon compound.

30

Just for illustration one example could be CYP71E1 from *Sorghum bicolor* that starting from *p*-hydroxyphenylacetonitrile is involved the biosynthesis pathway leading to a low molecular

21

weight aglycon compound *p*-hydroxymandelonitrile (see figure 1 and Tattersall, DB et al, Science (2001) 293:1826-8).

Further examples are the genes involved in the biosynthesis pathway leading to a low molecular
5   weight aglycon compound vanillin as described in working examples herein. Even further examples are given in Szczebara et al., Nature Biotechnology (2003), 21:143-149. This article describes a recombinant yeast cell capable of producing hydrocortisone from a simple carbon source. The yeast cell comprised eight recombinantly introduced genes involved in the biosynthesis pathway.
10

As said above the skilled person has at his disposal a number of different biosynthesis pathway genes. Further, he may by use of known routine methods easily identify further suitable biosynthesis pathway genes. For instance, the numerous biosynthesis pathway gene sequences may be used to make appropriate PCR primers to clone new suitable biosynthesis pathway
15   genes. This could e.g. be done by a method comprising following steps:
(a) preparing a cDNA library from a cell (e.g. plant tissue cell) expressing biosynthesis pathway genes of interest,
(b) using relevant known biosynthesis pathway gene sequences to make appropriate PCR primers at to amplify part of the biosynthesis pathway gene encoding cDNA from the cDNA
20   library,
(c) using the DNA obtained in steps (b) as a probe to screen the DNA library prepared from cell expressing the biosynthesis pathway genes of interest, and
(e) identifying and purifying vector DNA comprising an open reading frame encoding a biosynthesis pathway gene of interest.
25

As explained above a cell used in a method as described herein comprises a gene encoding a product involved in the biosynthesis pathway. The cell may comprise more than one gene encoding a product involved in the biosynthesis pathway.

30   A suitable example is the transgenic *Arabidopsis thaliana* cell described in Tattersall, DB et al, Science (2001) 293:1826-8. It comprises the two biosynthesis pathway genes CYP79A1 and

CYP71E1 and can therefore make aglycon compound *p*-hydroxymandelonitrile from tyrosine (see Figure 1 herein).

A further example is the E. coli cell described in working examples herein that comprises
5   sufficient biosynthesis pathway genes to make the aglycon vanillin from glucose.

A gene encoding a product involved in the biosynthesis pathway as described herein may be introduced into a cell in order to make a cell wherein the cell expresses a heterologous gene encoding a product involved in the biosynthesis pathway as described herein, in particular a
10 microorganism cell or a filamentous fungi cell that expresses a heterologous gene encoding a product involved in the biosynthesis pathway as described herein.

<u>Low molecular weight organic aglycon compound</u>

15 As said above, the low molecular weight organic aglycon compound, as described herein, has a molecular weight from 50 to 3000. Preferably, the low molecular weight organic aglycon compound has a molecular weight from 50 to 2000, more preferably a molecular weight from 50 to 1000, and even more preferably a molecular weight from 50 to 750.

20 Further, the low molecular weight organic aglycon compound is preferably a compound selected from the group consisting of more or less saturated Alkyl-, Cycloalkyl-, Cycloalkylalkyl-, Arallyl- and Aryl, with 1 to 50 C-atoms and 0 to 20 heteroatoms and optionally substituted, in particular with Hydroxy-, Amino-, Sulfide-, Carboxy-, or Nitro groups, at the 1 to 56 C-atoms and/or 0 to 20 Heteroatoms; more preferably a compound selected from the group consisting of
25 more or less saturated Alkyl-, Cycloalkyl-, Cycloalkylalkyl-, Arallyl- and Aryl, with 1 to 32 C-atoms and 0 to 10 heteroatoms and optionally substituted, in particular with Hydroxy-, Amino-, Sulfide-, Carboxy-, or Nitro groups, at the 1 to 32 C-atoms and/or 0 to 10 Heteroatoms.

In a preferred embodiment, the low molecular weight organic aglycon compound is an alcohol,
30 in particular an aromatic alcohol.

23

Plants may be seen as the organic chemists per excellence in nature. More than 200.000 different natural products are known from plants. These enable plants to deter herbivores and pests, attract pollinators, communicate with other plants and constantly adapt to climatic changes. As explained before the majority of these compounds may be termed secondary metabolites.

5

The term "secondary metabolite" relates to that plants and microbes synthesize a large number of natural substances, in particular secondary metabolites, with diverse and generally unclear function. In contrast to the primary metabolites (eg amino acids, sugars, fatty acids), which are involved in fundamental functions like metabolism, growth, maintenance and survival, secondary

10 metabolites are not required for fundamental functions. The term secondary metabolite should herein be understood in view of such, according to the art, standard description of the term.

In a preferred embodiment the low molecular weight organic aglycon compound is a secondary metabolite compound, preferably a plant secondary metabolite compound.

15

Examples of preferred secondary metabolite compound classes are:
- Terpenoids
- Alkaloids
- Phenylpropanoids
20 - Phenyl derivatives
- Hexanol derivatives
- Flavonoids
- Coumarins, stilbenes
- Cyanohydrins
25 - Steroids
- Hormones
- Antibiotics
- Herbicides
- and glucosinolates

30

Examples of preferred individual low molecular weight organic aglycon compounds is a compound selected from the list consisting of:

24

mandelonitrile, p-hydroxymandelonitrile, acetone cyanohydrin, hydroquinone, benzyl alcohol, p-hydroxybenzyl alcohol, benzoic acid, p-hydroxybenzoic acid, p-hydroxybenzaldehyde, gentisic acid, caffeic acid, 2-hydroxy cinnamic acid, resveratrol (stilbene), salicylic acid, p-hydroxymandelic acid, vanillic acid, vanillin, 2-hydroxy methoxybenzylalcohol, quercetin,

5   cyanidin (anthocyanidin), biochanin A (isoflavone), naringenin (flavanone), apigenin (flavone), 1-hexanol, trans hexen-1-ol, cis hexen-1-ol, 3-methyl hexen-1-ol, 3-methyl hexen-1-ol, indole acetic acid (plant hormone), geraniol (monoterpenoid), tomatidine (alkaloid), nerol, p-citronellol, saligerin, resorcinol, thymol, phenol, methylvanillin, p-hydroxyacetophenone, p-methoxyphenol, 3,4-dimethoxyphenol, coniferyl alcohol, o-coumaric acid, p-coumaric adic,

10   caffeic acid, luteolin, quercitin-, catechinl-, cyadinin, p-hydroxybenzoic acid, abscisic acid (phytohormone), 2,4,5-trichlorophenol (TCP), pentachlorophenol, 4-nitrophenol, 3,5-dibromo-4-hydrobenzoic acid, tetracycline, and 2,2-bis-(4-chlorophenyl)-acetic acid.

Growing a cell

15

In a method as described herein, the cell should be grown under conditions where it produces the aglycon and the corresponding glycosylated form of the aglycon. An important point in relation to the growth of the cell is that adequate intermediate compounds must be available to the cell. This means for example that if the cell is e.g. an E. coli cell comprising adequate genes involved

20   in the biosynthesis pathway leading e.g. to the aglycon compound vanillin from e.g. glucose, then the E. coli cell should be fermented under conditions where glucose is available to the cell.

If the cell is e.g. a plant cell comprising adequate genes involved in the biosynthesis pathway leading to the aglycon compound from e.g. tyrosine then the plant cell should be grown under

25   conditions where tyrosine is available to the growing plant.

The skilled person knows how to grow a specific cell of interest to ensure this.

A method of producing a low molecular weight organic aglycon compound

30

As described above the third aspect of the invention relates to a method of producing a low molecular weight organic aglycon compound comprising following steps:

25

a) growing a cell, which comprises a gene encoding a product involved in the biosynthesis pathway leading to a low molecular weight organic aglycon compound and a glycosyltransferase gene encoding a glycosyltransferase capable of glycosylating the produced aglycon, under suitable conditions wherein the cell produces the aglycon and

5   the associated glycosylated form of the aglycon;

b) deglycosylating the glycosylated form of the aglycon; and

c) recovering the aglycon compound;

(i) wherein the low molecular weight organic aglycon compound has a molecular weight from 50 to 3000, and

10   (ii) wherein the glycosyltransferase is a glycosyltransferase capable of conjugating a sugar to the aglycon compound.

All embodiments above are also embodiments of this third aspect. An essential step of this method is the deglycosylating step b). This step is further described below, where some non-

15 limiting examples are included to illustrate a number of technical advantages in relation to this deglycosylating step.

Though glucosides are often desirable natural products and attempts to use transgenic glucosyl transferases to produce them have been taken (e.g. Arend et al, 2001, Biotechnology and

20 Bioengineering 76: 126-131) the corresponding aglucone can be more commercially interesting. One example is vanillin, a natural flavour of significant commercial interest. Vanillin is a phenolic compound that accumulates in the fruits of the orchid Vanilla sp. in a glycosylated form, gluco-vanillin. In order to obtain the desired natural flavour, gluco-vanillin must be deglucosylated. This is achieved by fermentation (curing) of the fruits, so-called vanilla beans, whereby

25 endogenous beta-glucosidases are activated.

In the step b) of the method of the third aspect of the invention, the glycosylated intermediate of the desired natural product is subjected to a deglycosylating step. This may be done by chemical hydrolysis according to known methods in the art or enzymatically by e.g. use an enzyme with

30 beta-glycosidase activity. Numerous suitable beta-glycosidases are known to the skilled person. This can e.g. be achieved first by recovering glycosylated form of the aglycon for instance by extracting the glucosylated intermediate in a suitable solvent, e.g. methanol, or by collecting it

26

after excretion from the producing organism or plant. Secondly, the glucosylated intermediate is purified and exposed to a beta-glucosidase in vitro or to an adequate chemical hydrolysis.

Alternatively, the stabilized glucosylated intermediate can be let alone in the plant and be allowed
5   to accumulate in cellular compartments or tissues where it is protected from endogenous beta-glucosidase activity. In such a protected spatial environment the glucosylated intermediate is no longer exposed to enzymatic activity that could further metabolize its deglucosylated equivalent. It could, however, also be protected in time, if the desired natural product was kept in its glucosylated form until developmental changes in the plant had led to a significant decrease in
10 the activity of the enzymes that could otherwise metabolize its deglucosylated form.

It is preferred for the present invention that glycosylation of the desired aglycon is uncoupled from its subsequent deglycosylation, since the aglycon would otherwise be subject to further metabolic processing. As indicated above, this uncoupling can be either in time or space.
15 Preferably it is in space.

In the final step c) of the method of the third aspect of invention, the desired aglycon is recovered.

20 The present method will address at least three problems related to biotechnological production of organic molecules. First, it will allow for increased production of organic molecules that are stable and constitute the final product of the respective biosynthetic pathway of the production organism. Second, it will allow for increased yield of organic molecules that are not the end product of the respective biosynthetic pathway and are consequently further metabolized by the
25 production organism. Third, it will allow for increased production of organic molecules that are toxic to the production organism.

Regarding toxicity is show in examples 1 and 2 that the presence of a heterologous UDPG-glucosyltransferase in a microorganism can increase its tolerance to vanillin through
30 glucosylation. This principle is evidently not limited to vanillin but can be applied to any toxic substance that can be converted into a less toxic glucoside by the heterologous UDPG-glucosyltransferase, including e.g. taxol.

This approach can be helpful in increasing tolerance to a desired organic molecule, which is the end product of its biosynthetic pathway and is therefore accumulated in the production organism to concentrations that might be limiting production. However, the approach might also address

5 detoxification of substances that are structurally or biosynthetically unrelated to the desired molecule. Such substances could be byproducts of the desired biosynthetic pathway or contaminants in the growth medium.

In the industrial fermentation of ethanol from lignocellulose, vanillin has been reported to be one

10 of the strongest inhibitors among the hydrolysis byproducts (Delgenes et al,1996, Enzyme Microb Technol, 19: 220) and it acts as a strong growth inhibitor at concentrations of 5 g/l in the medium (Pfeifer et al, 1984, Biotechnol Lett 6: 541). Accordingly, fermentation of lignocellulose using microorganisms expressing a heterologous UDPG-glucosyltransferase might not only increase the yield of ethanol but could potentially also lead to a means for parallel production of

15 commercially valuable vanillin after recovery and deglucosylation of non-toxic vanillin glucoside.

The method as described herein are of direct importance to biotechnological production of several organic molecules, since it can increase yield of organic molecules that are stable and constitute the final product of the respective biosynthetic pathway of the production organism.

20 The feasibility of this approach is shown in examples 3 and 4 using production of vanillin in a microbial system as an example. However, it is obvious for those skilled in the art that this principle is not limited to production of vanillin from ferulic acid, but can be applied in virtually any biosynthetic pathway where the desired organic molecule is the end product and opposes at least some inhibition to production.

25

When the desired organic molecule is the end product of its biosynthetic pathway it will itself in many cases be a limiting factor in the rate of production. This is due to product inhibition of enzymes in the biosynthetic pathway and thus leads to reduced production rate. Instead of achieving high levels of the desired end product, an intermediate product might build up and

30 either accumulate or be directed into other metabolic pathways and consequently become lost for the desired biosynthetic pathway.

28

The method will overcome this product inhibition by adding an additional step to the biosynthetic pathway, so the inhibiting product is removed and thereby is no longer able to inhibit the enzyme. When biosynthesis is no longer suppressed by product inhibition the turnover of the initial substrates and their conversion into first the desired product and subsequently into
5   its glucosylated derivative will substantially increase. According to the method, the glucosylated derivative is then extracted and converted back into the desired aglucone by e.g. beta-glucosidase activity.

The desired organic molecule might, however, not always be the end product of its biosynthetic
10 pathway in the production organism. In such cases, it is further metabolized and might eventually be lost for commercial recovery. In examples 5 and 6 is demonstrated how the method can be applied to rescue such intermediates. In the examples, an aldehyde oxime is rescued by glucosylation of a heterologous UDPG-glucosyltransferase, but it is evident for those skilled in the art that the principle is general and can be used for any intermediate product of desire that
15 can be glucosylated. The examples address a molecule of desire, the oxime aldehyde, which is not naturally produced in the production organism, but in other examples the organic molecule of desire might as well be a substance that is produced naturally.

The sorghum cytochrome P450 enzyme complex CYP79 catalyses the conversion of the amino
20 acid tyrosine into an aldehyde oxime, p-hydroxyphenylacetaldoxime (Bak et al, 2000, Plant Physiol 123: 1437). Attempts to transfer the sorghum CYP79 gene to other plants or microorganisms leads to very low production of the oxime, since it is toxic and is being further metabolised to at least two presently unidentified substances, X and Y, that might be nitrile and alcohol derivates (Halkier et al, 1995, Arch Biochem Biophys 322: 369; Bak et al, 2000, Plant
25 Physiol 123: 1437). In plants, e.g. tobacco and Arabidopsis, the oxime is also glucosylated into p-hydroxyphenyl-(acetaldoxime glucoside) by an oxime specific UDPG-glucosyl transferase.

It is a general principle of the method that a glucosylated form of the desired organic molecule becomes the final product produced in the production organism. In addition to the advantages
30 this principle can have in yield, it might also posses some benefits during purification or extraction of the desired organic molecule. This is demonstrated in example 7, where it is exploited that the solubility of the desired molecule changes after glucosylation.

This principle can be useful if the desired molecule is difficult to separate from other substances present in the production organism or the growth medium. The glucosylated form could e.g. be exported to another compartment than the contaminating molecule, thereby facilitating

5 .purification. Alternatively, it could be excreted to the growth medium, whereas the contaminating molecule is left alone within the organism. Moreover, the purification process could utilize that the glucosylated form of the desired molecule has novel chemical properties, including not only solubility but also chromatographic properties etc.

10 <u>Method to selecting transgenic organisms with increased biosynthesis flow</u>

In example 6, is shown an example of how the method of the third aspect of the invention can be utilized to establish commercial production of p-hydroxyphenylacetaldoxime in microorganisms. This is achieved by transferring both the sorghum CYP79 gene and the oxime specific UDPG-

15 glucosyltransferase (see Figure 1) into the microorganism. This results in the production of p-hydroxyphenyl-(acetaldoxime glucoside), which is stable and non-toxic. Moreover, this glucoside can be extracted and converted into the desired p-hydroxyphenylacetaldoxime by e.g. in vitro beta-glucosidase activity.

20 Using this approach, the method not only makes the production of the desired molecule, the oxime, possible. It also allows for the selection of transgenic microorganisms with high expression levels of the sorghum CYP79 in a very active form, since the toxic product of the enzyme is readily detoxified by glucosylation. If the oxime specific UDPG-glucosyl transferase was not present, natural selection would favor microorganisms harboring the CYP79 gene in a

25 low expressing state and in a mutated form with less activity.

The example discussed above, illustrates how the method can be utilized to obtain, through selection, more efficient production organisms. This principle is not restricted to the example above, but will obviously apply for many other biosynthetic pathways and production organisms.

30

Accordingly, as said above a fourth aspect of the invention relates to a method for selecting a cell with increased production of a glycosylated form of a low molecular weight organic aglycon compound comprising following steps:

    a) growing a cell, which comprises a gene encoding a product involved in the

5   biosynthesis pathway leading to a low molecular weight organic aglycon compound and a glycosyltransferase gene encoding a glycosyltransferase capable of glycosylating the produced aglycon, under suitable conditions wherein the cell produces the aglycon and the corresponding glycosylated form of the aglycon;

    b) treating the cell in a way that changes the expression level of at least one gene

10   involved in the biosynthesis pathway leading to a low molecular weight organic aglycon and/or the glycosyltransferase gene capable of glycosylating the produced aglycon in order to make a library of cells with different expression levels of the genes; and

    c) selecting a cell that produces a higher amount of the glycosylated form of the aglycon as compared to the cell of step a);

15   (i) wherein the low molecular weight organic aglycon compound has a molecular weight from 50 to 3000, and

          (ii) wherein the glycosyltransferase is a glycosyltransferase capable of conjugating a sugar to the aglycon compound.

20   The term "library of cells" may herein also be termed "population of cells". The library of cells may comprise as little as two different cells.

The term "different expression levels of the genes" may be a library comprising individual cells with both increased or decreased expression levels of the genes. Preferably, the library mainly

25 comprises individual cells with increased expression levels of the genes.

Wherein the cell is within a plant the library will comprise a library of different plants. Preferably the library comprises 10^2 plants, more preferably 10^3 plants, even more preferably 10^5 plants, even more preferably 10^6 plants.

30

When the cell is a microorganism the library may normally easily be made relatively bigger. Consequently, when the cell is a microorganism the library comprises 10^5 cells, more preferably 10^7 cells, even more preferably 10^8 cells, even more preferably 10^9 cells.

5   The selected cell of this method may be a preferred cell to use in a method of producing a low molecular weight organic compound of the first aspect of the invention or a method of producing a low molecular weight organic aglycon compound of the third aspect of the inventions or in relation to the different embodiments of these methods to make a low molecular weight organic compound.

10

Accordingly, an embodiment of the invention relates to a method where there is first selected a cell as described in the fourth aspect above and thereafter this cell is used in a method of producing a low molecular weight organic compound of the first aspect of the invention or a method of producing a low molecular weight organic aglycon compound of the third aspect of

15   the inventions or in relation to the different embodiments of these methods to make a low molecular weight organic compound.

The treating of the cell step b) above may be done by numerous different strategies known to the skilled person. Examples are mutagenesis such as UV treatment, adequate chemical treatment to

20   make DNA mutations, random mutagenesis of e.g. specific promoters of the relevant genes, shuffling of cells to make a library of shuffled cells and etc.

The selected cell of step c) should preferably produce 1.25 times higher amounts of the glycosylated form of the aglycon as compared to the cell of step a), more preferably the selected

25   cell of step c) should preferably produce 1.5 times higher amounts of the glycosylated form of the aglycon as compared to the cell of step a), even more preferably the selected cell of step c) should preferably produce 2 times higher amounts of the glycosylated form of the aglycon as compared to the cell of step a), and most preferably the selected cell of step c) should preferably produce 3 times higher amounts of the glycosylated form of the aglycon as compared to the cell

30   of step a).

32

The selecting may be done in a number of ways according to the art. For instance in a micro titer assay where each well comprises a sample of a specific cell and there is measured amounts of the glycosylated form of the aglycon. There are numerous other ways of doing this according to the general knowledge of the skilled person.

5

Example 8 describes how this method is used to make an *Arabidopsis thaliana* plant capable of producing increased mg of dhurrin per gram of fresh weight. The starting cell of step a) is the *Arabidopsis thaliana* transgenic cell described in Tattersall, DB et al, Science (2001) 293:1826-8. As explained above the *Arabidopsis thaliana* transgenic cell comprises the entire pathway for

10 synthesis of the cyanogenic glucoside dhurrin. It was demonstrated that the transgenic *Arabidopsis thaliana* plant was capable of producing 4 mg of dhurrin per gram of fresh weight. After performing the method as described in example 8 an *Arabidopsis thaliana* transgenic cell is selected in step c) that produces more than 6 mg of dhurrin per gram of fresh weight.

15 Without being limited to theory, it is believed to be the first time that a plant has been provided that is capable of producing more than 4 mg per gram of fresh weight of a glycosylated form of a low molecular weight organic aglycon compound.

Accordingly, as said above a fifth aspect of the invention relates to a plant capable of producing

20 more than 5 mg per gram of fresh weight of a glycosylated form of a low molecular weight organic aglycon compound,

(i) wherein the low molecular weight organic aglycon compound has a molecular weight from 50 to 3000.

25 Preferably, the plant is capable of producing more than 6 mg per gram of fresh weight of a glycosylated form of a low molecular weight organic aglycon compound, more preferably the plant is capable of producing more than 8 mg per gram of fresh weight of a glycosylated form of a low molecular weight organic aglycon compound. Preferably, the plant produces from 5 mg to 40 mg per gram of fresh weight of a glycosylated form of a low molecular weight organic

30 aglycon compound.

Preferably, the plant is a transgenic plant.

EXAMPLES:

General molecular biology methods

5

Unless otherwise mentioned the DNA manipulations and transformations were performed using standard methods of molecular biology (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995; Harwood, C. R., and Cutting, S.

10 M. (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons, 1990).

Enzymes for DNA manipulations were used according to the specifications of the suppliers.

EXAMPLE 1. ANALYSIS OF INCREASED TOLERANCE TO VANILLIN IN

15 *MICROORGANISMS EXPRESSING A UDPG-GLUCOSYL TRANSFERASE*

Vanillin sensitivity is determined in a number of microorganisms. The microorganisms includes the Escherichia coli strains DH5-alpha, TOP10, JM109 and KO1418; the Pseudomonas fluorescens strains DSM 50091, DSM 50108 and DSM 50124; the Bacillus subtilis strain DSM

20 704; and the Corynebacterium glutamicum strain DSM 20300. The microorganisms also include strains of Saccharomyces cerevisiae, S. uvarum, S. bayanus, S. paradoxus, S. kudriavzevii, S. mikatae, S. cariocanus, S. servazzii, S. castellii, S. kluyverii, Kluyveromyces lactis, Zygosaccharomyces fermentatii, Torulaspora delbruekii, Debaromyces orientalis and Schizosaccharomyces pombe.

25

The minimum inhibitory concentration of vanillin is determined by the two-fold serial dilution assay (Hufford et al, 1975, J Pharm Sci 4: 789). Furthermore, the concentration of vanillin necessary to inhibit growth by more than 50% is determined. Once the sensitivity of vanillin has been determined in the various bacterial and yeast strains a few of these are selected in order to

30 obtain microbial strains displaying a broad range of vanillin sensitivity.

34

The selected strains are transformed with a UDPG-glucosyl transferase gene, e.g. Sorghum bicolor UDPG-glucosyl transferase UGT85B1 (Jones et al, 1999, J Biol Chem 274: 35483), Arabidopsis thaliana UDPG-glucosyl transferase UGT89B1 (Lim et al, 2002, J Biol Chem 277: 586) and Rauvolfia serpentina arbutin synthase (Arend et al, 2001, Biotechnol Bioeng 76: 126).

5

For expression of UDPG-glucosyl transferase in E. coli , the IPTG-inducible expression vectors pSP19g10L, pKK223-3 and pET101D/Topo are employed. In addition, the newly constructed E. coli expression vectors using constitutive E. coli glycolytic gene promoters are used. For expression in P. fluorescens, the BHR expression vector pYanni3 are used. For expression of

10 UDPG-glucosyl transferase in yeast, the genes are PCR amplified and inserted into plasmid pJH259, in which the genes are expressed from the constitutive and strong glycolytic TPI1 promoter. Alternatively, the TPI1 promoter is exchanged with a PCR-amplified MET25 promoter, which is repressible by methionine.

15 The UDPG-glucosyl transferase expressing microorganisms are subjected to analysis of their sensitivity to vanillin in the growth medium as described above. An increased tolerance to vanillin, determined as an increase in either the minimum inhibitory concentration or the concentration necessary to inhibit growth by more than 50%, means that transgenic UDPG-glucosyl transferase activity has converted some or most of the applied vanillin into vanillin

20 glucoside, which is considerably less toxic.

EXAMPLE 2. IDENTIFICATION OF GLUCOSIDES IN MICROORGANISMS EXPRESSING A UDPG-GLUCOSYL TRANSFERASE

25 Microorganisms expressing a heterologous UDPG-glucosyl transferase will be grown in medium containing appropriate levels of vanillin or ethylvanillin. The microorganisms will be harvested and their content of glucosides will be extracted in methanol or other suitable solvents. The presence of vanillin glucoside or ethylvanillin glucoside will be established and their levels will be quantified. The content of vanillin glucoside and ethylvanillin glucoside will be compared in

30 transgenic and non-transgenic microorganisms as well as in microorganisms grown in medium with and without vanillin or ethylvanillin.

The presence of increased amounts of vanillin glucoside or ethylvanillin glucoside in UDPG-glucosyl transferase expressing microorganisms grown in medium containing vanillin or ethylvanillin will indicate that the aglucones are taken up and glucosylated by the transgenic organism.

5

EXAMPLE 3. INCREASED UPTAKE AND TURNOVER OF FERULIC ACID IN MICROORGANISMS EXPRESSING A UDPG-GLUCOSYL TRANSFERASE

10 Microorganisms capable of converting ferulic acid into vanillin are genetically modified to express a heterologous UDPG-glucosyl transferase. Streptomyces setonii strain ATCC 39116 is used for these studies since it has previously been employed for industrial production of vanillin from ferulic acid (Muheim & Lerch, 1999, Appl Microbiol Biotechnol 51: 456; Muheim et al, 1998, EP 0885968A1). Alternatively, Pseudomonas putida strain AN103 (Narbad & Gasson,

15 1998, Microbiol 144: 1397; Narbad et al, 1997, WO 97/35999), or Amycolatopsis sp. HR167 (Rabenhorst & Hopp, 1997, EP 0761817A2) are used. The microorganisms are transformed with the appropriate construct so as to express Sorghum bicolor UDPG-glucosyl transferase UGT85B1, Arabidopsis thaliana UDPG-glucosyl transferase UGT89B1 or Rauvolfia serpentina arbutin synthase.

20 The genetically modified microorganisms are grown in medium containing appropriate concentrations of ferulic acid. The uptake of ferulic acid is determined by following its concentration in the medium and its metabolic turnover are determined by analysis of the concentration of vanillin and vanillin glucoside in the microorganisms and the growth medium.

25 These values are compared to similar analysis from experiments carried out with non-transgenic microorganisms.

An increased uptake of feruollic acid by microorganisms expressing heterologous UDPG-glucosyl transferase and their accumulation of vanillin glucoside demonstrate that the glucosyl

30 transferase has increased the conversion of ferulic acid into vanillin, which is then subsequently converted into vanillin glucoside.

EXAMPLE 4. INCREASED YIELD OF VANILLIN THROUGH DEGLUCOSYLATION OF VANILLIN GLUCOSIDE PRODUCED IN MICROORGANISMS EXPRESSING A UDPG-GLUCOSYL TRANSFERASE

5

Microorganisms capable of converting ferulic acid into vanillin are transformed with a gene encoding a UDPG-glucosyl transferase and are grown in the presence of ferulic acid. The concentration of ferulic acid in the growth medium is monitored and kept at constant level in order to compensate for the amount taken up by the microorganisms and used for the synthesis

10 of vanillin. After a period of several days, vanillin is extracted from the microorganisms and quantified. In addition, vanillin glucoside will be extracted and converted into vanillin through deglucosylation by beta-glucosidase activity in vitro. The amount of recovered vanillin will be quantified.

15 Similar experiments and quantification of vanillin synthesised as an end product as well as vanillin recovered from in vitro deglucosylation of vanillin glucoside are performed in non-transformed microorganisms.

A greater amount of total vanillin extracted and recovered from UDPG-glucosyl transferase

20 expressing microorganisms as compared to non-transformed microorganisms demonstrates that the presence of a heterologous UDPG-glucosyl transferase can lead to more ferulic acid being channeled into the synthesis of vanillin and its glucosylated form, from which vanillin can later be recovered. Consequently, total yield of vanillin can be increased through expression of a UDPG-glucosyl transferase.

25

EXAMPLE 5. CLONING OF AN OXIME-SPECIFIC PLANT UDPG-GLUCOSYL TRANSFERASE

The sorghum CYP79 gene is inserted into an E. coli expression vector under the control of the

30 IPTG inducible lac Z promoter. The vector is used for transformation of E. coli, transformants are selected and IPTG induction of CYP79 is demonstrated. For expression cloning of an oxime-

specific plant UDPG-glucosyl transferase, an Arabidopsis cDNA library is cloned into a suitable vector, which is then used for transformation of the strain harboring the CYP79 gene.

Transformants are selected for oxime-specific UDPG-glucosyl transferase activity by IPTG

5 induction of the CYP79 gene. This will lead to production of toxic p-hydroxyphenylacetaldoxime. Transformants harboring the desired oxime-specific UDPG-glucosyl transferase activity are able to detoxify this compound by glucosylation into p-hydroxyphenyl-(acetaldoxime glucoside). These transformants are rescued and the gene is cloned by conventional techniques.

10

EXAMPLE 6. HIGH LEVEL PRODUCTION OF A TOXIC AND UNSTABLE OXIME ALDEHYDE

A gene encoding the Arabidopsis oxime specific UDPG-glucosyl transferase is inserted into and

15 E. coli expression vector under the control of a strong constitutive promoter. The vector is used for transformation of E. coli and transformants are selected. Transformants are subsequently screened for oxime specific UDPG-glucosyl transferase expression, and those with the highest level of expression are selected.

20 The selected transformants are subsequently used for transformation of another expression vector containing the sorghum CYP79 gene under control of a strong constitutive promoter. Transformants are selected and subsequently screened for high level expression of the CYP79 gene product. A further screening can select those with optimal CYP79 enzymatic activity based on their ability to acumulate p-hydroxyphenyl-(acetaldoxime glucoside).

25

EXAMPLE 7. FACILITATING PURIFICATION OF AN ORGANIC MOLECULE BY GLUCOSYLATION

30 The cell used in this example is the E. coli cell of Example 13 capable of producing vanillin glucoside.

38

In continuous fermentation the fermentor is inoculated with media for growth and the fermentation is started under aeration conditions.

The first 12 – 18 hours is run for cell growth and after 12 – 18 hours the fermentor is fed with
5   glucose for production of vanillin glucoside. In the fermentation the growth rate is linear and it is anticipated that the limiting factor is the solubility of vanillin glucoside. From other corresponding glucosides it is known that the solubility is app. 100 g/l at STP and increases at higher temperatures.

10   After approximately 30 hours the high concentration is reach and harvesting is started. The cells are separated and recycled to the fermentor.

The supernatant is either concentrated to the limit of vanillin glucoside solubility or directly run over a column with beta-glucosidase. The supernatant is recirculated to the fermentor. If other
15   products should build up it can be passed over a cleaning column before recirculation. It is anticipated to have a row of columns where one is being used in process and the others are cleaned and regenerated.

The product is recovered as crystals from the enzymatic treatment. In order to decrease the
20   amount of recirculated vanillin the temperature is lowered in connection with enzyme treatment.

*EXAMPLE 8. SELECTING OF A PLANT CELL WITH INCREASED DHURRIN
PRODUCTION.*

25   The starting cell of is the *Arabidopsis thaliana* transgenic cell described in Tattersall, DB et al, Science (2001) 293:1826-8. The *Arabidopsis thaliana* transgenic cell comprises the entire pathway for synthesis of the cyanogenic glucoside dhurrin. It was demonstrated that the transgenic *Arabidopsis thaliana* plant was capable of producing 4 mg of dhurrin per gram of fresh weight.

30
The cell capable of producing 4 mg of dhurrin is treated with γ-irradiation or a by introducing a gene having higher CYP71 expression in order to make a library of plant cells.

39

The library of cells are investigated and a *Arabidopsis thaliana* transgenic cell is selected that produces more than 6 mg of dhurrin per gram of fresh weight.

5 *EXAMPLE 9: Vanillin sensitivity of various strains of E. coli*

The three different E. coli strains TOP10, JM109, and KO1418 were grown for 18 hours in the appropriate media, after which serial dilutions in growth medium (dilution factors 1, 1/100, 1/10000 and 1/1000000) were made. Droplets of these cell suspensions were applied to Petri

10 dishes containing solid LB growth medium with various concentrations of vanillin, and the plates were incubated at the appropriate growth temperature for 24 hours (*E. coli*), after which they were photographed. The percentual (w/v) concentration of vanillin at which growth of a given microorganism at the 1/10000 dilution was not detectable, and at which growth at the 1/100 dilution was severely inhibited, was recorded. This number constituted the STV (Sensitive To

15 Vanillin) level. The STV numbers for the different microorganisms studied can be seen in Table 1.

Strain	Genotype	STV
TOP10	F- mcrA Delta (mrr-hsdRMS-mcrBC) Phi80lacZ Delta-M15 Delta-lacX74 recA1 deoR araD139 Delta (ara-leu)7697 galU galK rpsL (StrR) endA1 nupG	0.12
JM109	F'traD36 lacIq Delta (lacZ) M15 proA+B+/ e14- (McrA-) Delta (lac-proAB) thi gyrA96 (NalR) endA1 hsdR17 (rK- mK-) relA1 supE44 recA1	0.14
KO1418	F- Delta (codB-lacI) 3 relA1? bglA677::Tn10 spoT1 bglB676::Lambda-lacZ bglGo-67 thi-1	0.18

Table 1. Vanillin sensitivity for various *E. coli* strains on solid growth medium

20

EXAMPLE 10: PCR amplification of S. bicolor UGT85B1, A. thaliana UGT89B1 and R. serpentina arbutin synthase (AS) genes

40

Roche Pwo polymerase and a DNA Engine Thermocycler were used for all PCR amplifications. The oligonucleotides referred to in the text can be seen in Table 2.

Oligo JH#	Name	Sequence (5'-3')
1	SB_GT_KK_F	ATTAGAATTCATGGGCAGCAACGCGCCGCCGCCG
2	SB_GT_KK_R	ATTAAAGCTTTTACTGCTTGCCCCCGACCAGCAG
3	SB_GT_pET_F	CACCATGGGCAGCAACGCGCCGCCGCCG
4	SB_GT_pET_R	TTACTGCTTGCCCCCGACCAGCAG
5	SB_GT_S_F1	ATGGGCAGCAACGCGCCGCCT
6	SB_GT_S_F2	CGCAGCTGCCAGGGAGGCCGG
7	SB_GT_S_F3	GCCTCCGCCGGCCTCGCCGCC
8	SB_GT_S_F4	CAGACCACCAACTGCAGGCAG
9	SB_GT_S_R1	GAGAGGGAGAGGCCGTCGTCG
10	AT_GT_KK-F	ATTAGAATTCATGAAAGTGAACGAAGAAAACAAC
11	AT_GT_KK-R	ATTAAAGCTTTTATTTGTTTAGTCCTAAACTAACGAC
12	AT_GT_pET_F	ATGAAAGTGAACGAAGAAAACAAC
13	AT_GT_pET_R	TTATTTGTTTAGTCCTAAACTAACGAC
14	AT_GT_S_F1	ATGAAAGTGAACGAGGAAAAC
15	AT_GT_S_F2	GAATCCCTCGTTTCGATTTCT
16	AT_GT_S_F3	CTTGACGCACGTGAGGATAAC
17	AT_GT_S_F4	CCTGACACGGTGCCTGACCCG
18	AT_GT_S_R1	CGGAGGGGATTGAAGGGTGGG
19	AS_GT_EC_KK_F	ATTAGAATTCATGGAACATACCCCGCACATT
20	AS_GT_EC_KK_R	ATTAGAATTCTTATGTACTGGAAATTTTGTTC
21	AS_GT_EC_pET_F	CACCATGGAACATACCCCGCACATT
22	AS_GT_EC_pET_R	TTATGTACTGGAAATTTTGTTC
23	AS_GT_S_F1	ATGGAGCATACACCTCACAT
24	AS_GT_S_F2	GACGGCCATGTGCCTGTCTC
25	AS_GT_S_F3	GGGGCAGTCTCCCATAATCA

26	AS_GT_S_F4	AGGGTCTTAAAGTGGCCCTG
27	AS_GT_S_R1	TACGGGTCTCTATCCTAACA
28	Pfba_F	ATTAGAATTCAAAAATCACAGGGCAGGGAAAC
29	Pfba_R	ATTAGGCGCGCCTCTAGAGTCTCTTGTCCTGTATC GTCGGG
30	PpfkA_F	ATTAGAATTCTCAGTATAAAAGAGAGCCAGAC
31	PpfkA_R	ATTAGGCGCGCCTCTAGAGACTACCTCTGAACTTT GGAAT
32	PgapA_F	ATTAGAATTCTTGCTCACATCTCACTTTAATC
33	PgapA_R	ATTAGGCGCGCCTCTAGAATATTCCACCAGCTATT TGTTA
34	PtpiA_F	ATTAGAATTCCAAAAAGCAAAGCCTTTGTGCC
35	PtpiA_R	ATTAGGCGCGCCTCTAGATTTAATTCTCCACGCTTA TAAG
36	TcysB_F	ATTAGGCGCGCCGGATCCTTTCTTGCGTTATTTTCG GCACC
37	TcysB_R	ATTAAAGCTTGAAAAACCGCCAGCCAGGCTTT
38	SB_GT_EC_NP_F	ATTATCTAGAATGGGCAGCAACGCGCCGCCGCCG
39	SB_GT_EC_NP_R	ATTAGGATCCTTACTGCTTGCCCCCGACCAGCAG
40	AT_GT_EC_NP_F	ATTATCTAGAATGAAAGTGAACGAAGAAAACAAC
41	AT_GT_EC_NP_R	ATTAGGATCCTTACCACCGTTCTATCTCCATCTTC
42	RS_GT_EC_NP_F	ATTATCTAGAATGGAACATACCCCGCACATT
43	RS_GT_EC_NP_R	ATTAGGATCCTTATGTACTGGAAATTTTGTTC

Table 2. Oligonucleotides used in this study

UGT85B1, UGT89B1 and AS for IPTG-controlled expression in E. coli

5

For amplification of UGT85B1 for use in the *E. coli* vector pKK223-3 (Amersham-Pharmacia Biotech), the oligonucletides JH#1 and JH#2 (Table 2) were used, with the plasmid pSP19g10L-UGT85B1 (Jones et al., 1999, J Biol Chem 274: 35483) as template for the reaction. The

reaction conditions employed were 94 °C, 2 min., 1 cycle, 94 °C, 30 sec., gradient 50-60 °C, 1 min., 72 °C, 2 min., 30 cycles, followed by 72 °C, 7 min., 1 cycle. The reaction contained 5 % DMSO. Reaction samples containing a fragment of the expected size of 1.5 kb were combined, and used for ligation into the pCR-Blunt II-Topo vector. Clones containing *EcoRI* inserts of 1.5

5   kb were sequenced with the primers JH#5-9. A clone with a correct DNA sequence was identified and named pJH400. The UGT85B1 ORF was liberated from pJH400 with *EcoRI-HindII* (these restriction sites were included at the 5'-termini of the primers) and inserted in an *EcoRI-HindIII* digested pKK223-3 plasmid. A clone with a correct UGT85B1 insert was identified and named pJH401.

10

For amplification of UGT85B1 for use in the *E. coli* vector pET101-D/Topo, an identical PCR reaction was performed, only using the primers JH#3 and 4. The same PCR program was employed, and a fragment of the correct size of 1.5 kb was directionally inserted in the expression vector pET101-D/Topo. The inserts of several clones were sequenced using primers

15   JH#5-9. One correct clone was named pJH402.

For amplification of UGT89B1 for use in the *E. coli* vector pKK223-3, the oligonucletides JH#10 and JH#11 (Table 2) were used, with genomic *Arabidopsis thaliana* DNA (var. Columbia Col-0) as template for the reaction. The reaction conditions employed were 94 °C, 2 min., 1

20   cycle, 94 °C, 30 sec., gradient 50-60 °C, 1 min., 72 °C, 2 min., 30 cycles, followed by 72 °C, 7 min., 1 cycle. Reaction samples containing a fragment of the expected size of 1.4 kb were combined, and used for ligation into the pCR-Blunt II-Topo vector. Clones containing *EcoRI* inserts of 1.4 kb were sequenced with the primers JH#14-18. A clone with a correct DNA sequence was identified and named pJH462. The UGT89B1 ORF was liberated from pJH462

25   with *EcoRI-HindII* (these restriction sites were included at the 5'-termini of the primers) and inserted in an *EcoRI-HindIII* digested pKK223-3 plasmid. A clone with a correct UGT89B1 insert was identified and named pJH463.

For amplification of UGT89B1 for use in the *E. coli* vector pET101-D/Topo, an identical PCR

30   reaction was performed, only using the primers JH#12 and 13. The same PCR program was employed, and a fragment of the correct size of 1.4 kb was directionally inserted in the

expression vector pET101-D/Topo. The inserts of several clones were sequenced using primers JH#14-18. One correct clone was named pJH406.

For amplification of AS for use in the *E. coli* vector pKK223-3, the oligonucletides JH#19 and
5 JH#20 (Table 2) were used, with the plasmid pQE60-AS (Arend et al., 2001, Biotechnol Bioeng 76: 126) as template for the reaction. The reaction conditions employed were 94 °C, 2 min., 1 cycle, 94 °C, 30 sec., gradient 48-55 °C, 1 min., 72 °C, 2 min., 30 cycles, followed by 72 °C, 7 min., 1 cycle. Reaction samples containing a fragment of the expected size of 1.4 kb were combined, and used for ligation into the pCR-Blunt II-Topovector. Clones containing *Eco*RI
10 inserts of 1.5 kb were sequenced with the primers JH#23-27. A clone with a correct DNA sequence was identified and named pJH409. The AS ORF was liberated from pJH409 with *Eco*RI (*Eco*RI sites were included at the 5'-termini of both primers) and inserted in an *Eco*RI digested pKK223-3 plasmid. A clone with a correct AS insert in the correct orientation was identified and named pJH410.
15

For amplification of AS for use in the *E. coli* vector pET101-D/Topo, an identical PCR reaction was performed, only using the primers JH#21 and 22. The same PCR program was employed, and a fragment of the correct size of 1.4 kb was directionally inserted in the expression vector pET101-D/Topo. The inserts of several clones were sequenced using primers JH#23-27. One
20 correct clone was named pJH411.

UGT85B1, UGT89B1 and AS for constitutive expression in *E. coli*

A series of tailored expression systems for UGT85B1 and AS were constructed in which the
25 glucosyl transferase genes were controlled by one of four glycolytic *E. coli* gene promoters: *fba* (primers JH#28 and 29), *pfkA* (JH#30 and 31), *tpiA* (JH# 32 and 33) and *gapA* (JH#34 and 35) promoters, and all by the *E. coli cys*B terminator (primers JH#27 and 28) sequences. All constructions were based on the following scheme: The promoter fragment was PCR amplified from *E. coli* DH5α genomic DNA, inserted *Bam*HI-*Asc*I (these sites were present in the primers)
30 in pKOL30 (Olesen *et al.*, 2000, Yeast 16: 1035). In the resulting construct the *cys*B fragment was then inserted *Asc*I-*Hind*III (sites present in primers). Finally, in the resulting construct, PCR amplified UGT85B1 (primers JH#38 and 39), UGT89B1 (primers JH#40 and 41) or AS (JH# 42

44

and 43) were then inserted *Xba*I-*Eco*RI (these sites were present inside the *Asc*I sites in the 3'-end primer used for promoter amplification and in the 5'-end primer used for the terminator amplification, as well as in the primers used for amplification of the UGT and AS genes).

5   The PCR reaction conditions employed were 94 °C, 2 min., 1 cycle, 94 °C, 30 sec., 55 °C, 1 min. (for promoter and terminator fragments, as well as UGT fragments) or 48 °C, 1 min. (for AS fragment), 72 °C, 2 min., 30 cycles, followed by 72 °C, 7 min., 1 cycle. For amplification of UGT85B1, 5 % DMSO was included. Reaction samples containing a fragment of the expected sizes were combined, gel purified and used for cloning experiments as described above.

10

The resulting plasmids were pJH430 (*fba*-UGT85B1), pJH431 (*pfk*A-UGT85B1), pJH432(*gapA*A-UGT85B1), pJH433 (*tpi*A-UGT85B1), pJH434 (*fba*-UGT89B1), pJH435 (*pfk*A-UGT89B1), pJH436 (*gap*A-UGT89B1), pJH437 (*tpi*A-UGT89B1), pJH438 (*fba*-AS), pJH439 (*pfk*A-AS), pJH440 (*gap*A-AS) and pJH441 (*tpi*A-AS).

15

EXAMPLE 11: Vanillin detoxification by expression of UGT or AS genes E. coli

The *E. coli* strains TOP10, JM109, and KO1418 were all transformed with the constructed plasmids pJH401, pJH402, pJH411 and pJH412, and pKK223-3 as control, employing standard
20 transformation protocols. Transformants were selected for ampicilin resistance, and two transformants of each *E. coli* strain with each plasmid were kept for expression experiments. The *E. coli* transformants were inoculated from plate cultures into 2 ml liquid growth medium (LB medium containing ampicilin at 100 µg/ml), and allowed to grow for 20 hours at 37 °C. The precultures were diluted 100 times 10^4 times and 10^6 times in growth medium, and 4µl droplets
25 of these cell suspensions were applied to the surface of Petri dishes containing solid LB-ampicilin medium containing varying concentrations of vanillin (based on the STV determinations described above), and without or with (to induce gene expression) 1 mM isopropyl thiogalactoside (IPTG). The plates were incubated at 37 °C for 24 hours, after which growth on the various concentrations of vanillin was monitored and recorded. The results are summarized
30 in Table 1.

45

E. coli strain \ % Vanillin	0 %	0.08 %	0.12 %	0.16 %	0.2 %	IPTG induction
JM109 [pKK223-3]	++	++	++	-	-	No
	++	++	++	-	-	Yes
JM109 [pJH401]	++	++	++	-	-	No
	++	++	++	-	-	Yes
JM109 [pJH402]	++	++	++	+	-	No
	++	++	++	++	-	Yes
JM109 [pJH410]	++	++	++	++	-	No
	++	++	++	+	-	Yes
KO1418 [pKK223-3]	++	++	++	-	-	No
	++	++	++	++	-	Yes
KO1418 [pJH401]	++	++	++	-	-	No
	++	++	++	++	-	Yes
KO1418 [pJH402]	++	++	++	+	-	No
	++	++	++	++	-	Yes
KO1418 [pJH410]	++	++	++	++	-	No
	++	++	++	++	++	Yes

Table 1. Effect of IPTG-induced expression of *S. bicolor* UGT85B1 or *R. serpentina* AS on the toxicity of vanillin on three different strains of *E. coli*. -: No growth; +: weak growth; ++: good growth.

5

From these experiments we conclude that expression of *S. bicolor* UGT85B1 is possible in some *E. coli* strains and with some types of IPTG-inducible gene promoters, and that a stronger vanillin detoxification can be obtained by expression of the AS gene, but only in an *E. coli* strain in which the phospho-β-glucosidase encoding *bgl* locus has been inactivated (strain KO1418).

10

For experimentation with constitutive expression of UGT85B1 and AS, the *E. coli* strains JM109, and KO1418 were transformed with the constructed plasmids pJH 430, pJH431, pJH432, pJH433, pJH434, pJH435, pJH436, pJH437, pJH438, pJH439, pJH440, and pJH441,

46

and pKOL30 as control, employing standard transformation protocols. Transformants were selected for ampicilin resistance, and two transformants of each *E. coli* strain with each plasmid were kept for expression experiments. The *E. coli* transformants were inoculated from plate cultures into 2 ml liquid growth medium (LB medium containing ampicilin at 100 µg/ml), and

5 allowed to grow for 20 hours at 37 °C. The precultures were diluted 100 times 10^4 times and 10^6 times in growth medium, and 4µl droplets of these cell suspensions were applied to the surface of Petri dishes containing solid LB-ampicilin medium containing varying concentrations of vanillin (based on the STV determinations described above). The plates were incubated at 37 °C for 24 hours, after which growth on the various concentrations of vanillin was monitored and

10 recorded. The results are summarized in Table 2. The results with *E. coli* strains JM109 and KO1418 with the plasmids pJH430, pJH431, pJH432 and pJH433 are summarized in Table 2 below.

E. coli strain \ % Vanillin	0 %	0.08 %	0.12 %	0.16 %
JM109 [pKOL30]	+++	+++	++	-
JM109 [pJH430]	+++	+++	+++	++
JM109 [pJH431]	+++	+++	+++	++
JM109 [pJH432]	+++	+++	+++	+
JM109 [pJH433]	+++	+++	+++	+
KO1418 [pKOL30]	+++	+++	++	+
KO1418 [pJH430]	+++	+++	+++	+++
KO1418 [pJH431]	+++	+++	+++	+++
KO1418 [pJH432]	+++	+++	+++	+
KO1418 [pJH433]	+++	+++	+++	+++

15 **Table 2.** Effect of constitutive expression of *S. bicolor* UGT85B1 or *R. serpentina* AS on the toxicity of vanillin on two different strains of *E. coli*. -: No growth; +: weak growth; ++: growth; +++: strong growth.

47

From these experiments we conclude that constitutive expression of glucosyl transferase genes in *E. coli* strain JM109 results in vanillin detoxification.

5   *EXAMPLE 12: Vanillin glucoside (VG) production in UGT85B1-, UGT89B1- or AS-expressing strains of E. coli*

Several *E. coli* strains expressing UGT85B1 or AS are tested for VG production by growth in liquid growth medium containing sublethal vanillin concentrations. The strains tested are JM109

10   and KO1418 containing either of the following plasmids: pKK223-3, pJH401, pJH402, pJH406, pJH463, pJH410, pKOL30, pJH430, pJH431, pJH432, pJH433, pJH434, pJH435, pJH436, pJH437, pJH438, pJH439, pJH440 and pJH441.

The *E. coli* strains are inoculated over night at 37 ˚C in 2 ml LB medium containing 100 µg/ml

15   ampicilin, and then diluted into 50 ml of the same growth medium (0.1 ml o.n. culture). Growth proceeds at 37 ˚C for 2 hours, and then IPTG is added to a concentration of 1 mM (0.5 ml 100 mM stock) to those strains containing IPTG-inducible UGT/AS-expression plasmids. The cell suspensions are then incubated at 28 ˚C for 1 hour, after which vanillin is added to a concentration of 0.05 % (83 µl 30 % ethanol stock). Growth then proceeds at 28 ˚C for 24

20   hours. Cultures are centrifuged LC-MS are employed to determine VG content in growth supernatant as well as lysates of cell pellets.

In another set of experiments, the same *E. coli* strains are grown in a similar way, but instead of vanillin, ^{14}C-labelled vanillin (5 mCi of 50 mCi/mol) is added to the growing cultures, after which

25   growth proceeds 28 ˚C for 1-24 hours. Supernatant samples are taken regularly as are cell samples. Cell lysates are produced and both growth supernatants and cell lysates are subjected to TLC (thin layer chromatography) as described (Jones et al., 1999, J Biol Chem 274: 35483). Employing autoradiography, radioactive vanillin and radioactive vanillin glucoside are detected.

48

By both of the above described analyses we are able to detect the presence of vanillin glucoside from cells expressing UGT or AS genes while no vanillin glucoside can be detected from growth of cells not expressing UGT or AS genes.

5 *EXAMPLE 13: Establishment of a de novo biosynthesis pathway for the supply of vanillin to microbial expressed glucosytransferases*

To establish a microbial pathway for the conversion of glucose to vanillin three heterologous enzymatic activities are expressed in the UDPG-glucosyltransferase expressing microorganism.

10

The first enzymatic activity is a 3-dehydroshikimate dehydratase, which "taps" out a distant vanillin precursor from the common aromatic amino acid biosynthetic pathway, namely 3-dehydroshikimate, and converts it to protocatechuic acid. 3-Dehydroshikimate dehydratase (3DHD) genes are known from *Neurospora crassa* (Ruthledge, 1984, Gene 32: 275),

15 *Aspergillus nidulans* (Hawkins et al., 1985, Curr Genet 9: 305), *Podospora pauciseta* (GenBank accession # AL627362) and *Acinetobacter calcoaceticus* (Elsemore & Ornston, 1995, J Bacteriol 177: 5971). The next enzyme necessary is an aromatic carboxylic acid reductase (ACAR) that can convert protocatechuic acid to protocatechualdehyde. ATP-dependent ACAR activities are found in certain actinomycetes (*Nocardia* sp.) (use of *Nocardia* ACAR patented:

20 Rosazza & Li, 2001, US 6261814B1), in *Neurospora crassa* (Gross & Zenk, 1969, Eur J Biochem 8: 413) (use of ACAR enzyme preparation patented: Frost, 2002,, US 6372461B1) and in a range of basidiomycetes, socalled "white-rot" fungi, which are lignin degraders (e.g. *Trametes, Dichomitus, Bjerkandera* and *Pleurotus* ("Oyster mushroom") sp. (Hage et al., 1999, Appl Microbiol Biotechnol 52: 834). No data on AARC protein or nucleotide sequence are

25 available, except for a short N-terminal protein sequence from the *Nocardia* enzyme (Li & Rosazza, 1997, J Bacteriol 179: 3482). Finally, a 3-*O*-methylation is necessary for the final conversion to vanillin. The candidate enzyme for this purpose is a strawberry *S*-adenosylmethionine:furaneol *O*-methyltransferase gene (FaOMT) (Wein et al., 2002, Plant J 31: 755), as this enzyme efficiently methylates vanillin at the 3-O. Alternative methylases include

30 aspen (Bugos et al., 1991), Plant Mol Biol 17: 1203), almond (Garcia-Mas et al., 1995, Plant Phys 108:1341) and *Vanilla planifolia* (Xue & Brodelius, 1998, Plant Physiol Biochem 36: 779)

caffeic acid OMTs. To avoid the accumulation of toxic intermediates the first gene expressed in a functional UGT-expressing microbial strain will be the methyl transferase gene. When this has been seen to work (i.e. producing vanillin glucoside from protocatechualdehyde), the aldehyde dehydrogenase is introduced, etc., until the intrinsic 3-dehydroshikimate-producing pathway is

5   reached.

The strawberry FaOMT gene is isolated by PCR, using *Fragraria x ananassa* (strawberry) cDNA as template DNA. The cDNA is isolated from maturing *F. ananassa* var. Elanta using the QBiogene Fastprep Pro Green kit, and from the resulting total RNA preparation cDNA is

10   synthesized employing the Invitrogen Superscript II Reverse transcriptase. This cDNA preparation is used for PCR amplification using FaOMT ORF-specific primers and *Pwo* polymerase (Roche Biochemicals). The resulting 1.1 kb FaOMT-containing DNA fragment is isolated and inserted between the *Xba*I and *Bam*HI sites in the inducible *E. coli* expression vector pJH-X1, resulting in plasmid pJH-X2.

15

E. coli strain JH1, which corresponds to *E. coli* JM109 containing plasmid pJH430 (expressing UGT85B1 from the *E. coli fba* promoter) is transformed with plasmid pJH-X2. The resulting *E. coli* strain JH2 is grown in liquid LB growth medium to which protocatechualdehyde is added. Expression is induced. The culture supernatant of the outgrown culture is subjected to LC-MS,

20   and vanillin glucoside is identified, meaning that a biosynthetic pathway that can convert protocatechualdehyde to vanillin glucoside has been established.

An AARC gene that is effective in the conversion of protocatechualdehyde to vanillin is isolated in the following manner: cDNA is synthesized from total RNA extracted from a white rot fungus

25   (chosen from the species *Pleurotus ostreatus*, *Trametes gibbosa* or *Dichomitus squalenes*) by the use of Invitrogen Superscript II Reverse transcriptase. A cDNA library is produced using the Clontech Creator Smart cDNA library construction system. The fungal cDNA inserts are transferred to the *E. coli* expression vector pJH-X1-Cre, which has been modified from vector pJH-X1 by the use of the Clontech Creator Acceptor Vector Construction system. A number of

30   20.000 clones from the resulting cDNA expression library are grown in liquid LB growth medium in microtiter plates (209 plates in total). Cell extracts from these clones are inoculates

50

with protocatechuic acid, ATP and NADPH, and samples from the enzymatic assays are subjected to LC-MS analysis, in pools of 96 clones. An enzymatic activity that results in the conversion of protocatechuic acid to protocatechuic aldehyde is identified in one pool. The original cDNA expression clones corresponding to the 96 enzyme assays from this pool are

5   grown again, and the assay procedure repeated. One clone is shown to contain a cDNA that when expressed leads to an enzymatic activity that can convert protocatechuic acid to protocatechuic aldehyde. The cDNA insert of this clone is subjected to DNA sequencing analysis, and after identification of this AARC gene, the gene is PCR amplified again in order to be able to insert it into the *E. coli* expression vector pJH-X2, resulting in plasmid pJH-X3.

10

E. coli strain JH1 (expressing UGT85B1) is transformed with plasmid pJH-X3. The resulting *E. coli* strain JH3 is grown in liquid LB growth medium to which protocatechuic acid is added. Expression is induced. The culture supernatant of the outgrown culture is subjected to LC-MS, and vanillin glucoside is identified, meaning that a biosynthetic pathway that can convert

15   protocatechuic acid to vanillin glucoside has been established.

A 3DHD gene is isolated from *Podospora pauciseta* in the following manner: Genomic DNA is isolated from *P. pauciseta* using the QBiogene Fastprep DNA system, and the 3DHD gene is PCR amplified using this genomic DNA as template from the reaction with *P. pauciseta* 3DHD-

20   specific primers #3 and #4 (Table 4), and the *Pwo* polymerase (Roche Biochemicals). The resulting 1.1 kb 3DHD gene fragment is inserted between the *Bam*HI and *Xba*I sites of the *E. coli* expression vector pJH-X3, resulting in plasmid pJH-Van. *E. coli* strain JH1 (expressing UGT85B1) is transformed with plasmid pJH-Van.

25   The resulting *E. coli* strain JH4 is grown in liquid LB growth medium. Expression is induced. The culture supernatant of the outgrown culture is subjected to LC-MS, and vanillin glucoside is identified, meaning that a biosynthetic pathway that can convert glucose to vanillin glucoside has been established.

51

E. coli strain JM109 is now transformed with plasmid pJH-Van. The resulting strain, JH5 now contains a biosynthesis pathway for vanillin production from glucose, while strain JH4 contains a biosynthesis pathway for vanillin production in addition to the glucosyl transferase-encoding UGT85B1 gene. Strains JH4 and JH5 are both grown in liquid LB growth medium, and gene

5   expression is induced. By the means described above we compare vanillin production in strain JH5 with vanillin glucoside production in strain JH4.

We observe that the *E. coli* strain containing a biosynthesis pathway for vanillin production in addition to a glucosyl transferase gene (strain JH4) produces higher amounts (on a molar basis)

10 of vanillin glucoside as compared to the amounts of the corresponding vanillin aglucone.

52

REFERENCES

The references mentioned below are a selection of the references that are considered most pertinent with respect to the present invention.

5

Paquette, S. et al, Phytochemistry 62 (2003) 399-413.

WO01/07631.

WO01/40491

Arend, J et al., Biotech. & Bioeng (2001) 78:126-131

10 Tattersall, DB et al, Science (2001) 293:1826-8

Moehs, CP et al, Plant Journal (1997) 11:227-236

US6372461